December 22, 2022 Press release - Non-regulatory Targovax announces that the TG01 study in multiple myeloma at Oslo University Hospital has received regulatory approvals to proceed
December 15, 2022 Press release - Non-regulatory Targovax starter samarbeid med Agenus for å teste TG som behandling mot bukspyttkjertelkreft
December 15, 2022 Press release - Non-regulatory Targovax announces clinical trial collaboration with Agenus to test TG mutant RAS vaccination in pancreatic cancer
December 7, 2022 Press release - Non-regulatory Targovax to present and attend at upcoming conferences
November 10, 2022 Press release - Non-regulatory Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement
October 20, 2022 Press release - Non-regulatory The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info
October 20, 2022 Press release - Non-regulatory The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research
October 5, 2022 Press release - Non-regulatory The ONCOS-102 phase 1b melanoma study selected for oral presentation at the SITC 2022 annual meeting
September 27, 2022 Press release - Non-regulatory Targovax’ studie i føflekkreft har blitt godkjent for oppstart av amerikanske FDA
September 27, 2022 Press release - Non-regulatory Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA
September 26, 2022 Press release - Non-regulatory Reminder: Targovax to host Investor Event 27 September
September 19, 2022 Press release - Non-regulatory Targovax arrangerer investormøte: Møt ledelsen 27. september
September 19, 2022 Press release - Non-regulatory Targovax to host Investor Event: Meet the Management on 27 September
August 11, 2022 Press release - Non-regulatory Targovax ASA: Invitation to Targovax’s second quarter and first half 2022 presentation, Thursday 18 August
June 23, 2022 Press release - Non-regulatory Targovax: FDA gir tillatelse til å starte kliniske studier med ny og forbedret TG01 kreftvaksine i USA
June 23, 2022 Press release - Non-regulatory Targovax announces that the FDA has granted authorization to initiate clinical trials with the enhanced TG01 RAS vaccine in the USA
June 23, 2022 Press release - Non-regulatory Targovax: FDA gir tillatelse til å starte kliniske studier med ny og forbedret TG01 kreftvaksine i USA
May 27, 2022 Press release - Non-regulatory Targovax announces publication of the two abstracts accepted for poster presentation at ASCO 2022
May 10, 2022 Press release - Non-regulatory Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma
May 3, 2022 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s first quarter 2022 results, Thursday 12 May
April 28, 2022 Press release - Non-regulatory Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO
April 26, 2022 Press release - Non-regulatory Targovax to present at 5th Neoantigen Summit Europe in Amsterdam
April 21, 2022 Press release - Non-regulatory Targovax ASA announces the appointment of two new Board Directors
March 9, 2022 Press release - Non-regulatory Targovax ASA: Poster presentation at the AACR Annual Meeting
March 7, 2022 Press release - Non-regulatory Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™
January 17, 2022 Press release - Non-regulatory Targovax granted Patents for ONCOS-102 in combination with chemotherapy in China and Japan